What is GateBio?
GateBio is a preclinical biotechnology company focused on pioneering Molecular Gates, a groundbreaking therapeutic modality. These small molecule drugs are engineered to target and neutralize specific extracellular proteins, offering a precise mechanism for disease intervention. The company's scientific foundation lies in its ability to create medicines that act directly within the cellular environment to remove disease-causing agents, positioning it at the forefront of protein-targeted therapeutics.
How much funding has GateBio raised?
GateBio has raised a total of $60M across 1 funding round:
Series A
$60M
Series A (2023): $60M with participation from Versant Ventures, Andreessen Horowitz, and ARCH VENTURE PARTNERS
Key Investors in GateBio
Versant Ventures
Versant Ventures is a venture capital firm specializing in building and funding innovative biotechnology companies globally, with a significant track record in IPOs and M&A transactions.
Andreessen Horowitz
Andreessen Horowitz is a venture capital firm that invests in both early-stage and established growth companies, headquartered in Menlo Park, California.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a venture capital firm focused on creating and investing in life sciences and advanced technology companies, often cofounding startups with scientists.
What's next for GateBio?
With this substantial enterprise-level backing, GateBio is poised to accelerate its preclinical development pipeline. The strategic investment will likely fuel further research and development efforts, including lead optimization, IND-enabling studies, and the expansion of its therapeutic programs. The company's focus on a novel mechanism of action suggests a long-term strategy aimed at establishing a new standard of care in areas with significant protein-related pathologies. Future growth will depend on successfully translating its innovative platform into clinical candidates.
See full GateBio company page
